Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Mohammed Alqinyah"'
Autor:
Hussain N. Alhamami, Abdullah M. Albogami, Mohammad M. Algahtani, Mohammed Alqinyah, Wael A. Alanazi, Fawaz Alasmari, Khalid Alhazzani, Ahmed Z. Alanazi, Yasseen A. Alassmrry, Abdullah S. Alhamed
Publikováno v:
Saudi Pharmaceutical Journal, Vol 32, Iss 3, Pp 101964- (2024)
Autism spectrum disorder (ASD) is a complex neurodevelopmental illness that often emerges in early childhood. The incidence of ASD has shown a notable rise in recent years. ASD is defined by deficits in social communication, and presence of rigid and
Externí odkaz:
https://doaj.org/article/ee4d6babcffd49a5aa4beaed78b8488d
Autor:
Abdullah S. Alhamed, Mohammed Alqinyah, Musab A. Alsufayan, Ibrahim A. Alhaydan, Yasseen A. Alassmrry, Hajar O. Alnefaie, Mohammad M. Algahtani, Adel F. Alghaith, Hussain N. Alhamami, Abdullah M. Albogami, Khalid Alhazzani, Alanazi AZ
Publikováno v:
Saudi Pharmaceutical Journal, Vol 31, Iss 2, Pp 245-254 (2023)
Store-operated calcium entry (SOCE) is an important pathway for calcium signaling that regulates calcium influx across the plasma membrane upon the depletion of calcium stores in the endoplasmic reticulum. SOCE participates in regulating a number of
Externí odkaz:
https://doaj.org/article/e0164ae4c5194d928d0127fd9b5eff20
Autor:
Khalid Alhazzani, Meshal Alsahli, Ahmed Z Alanazi, Mohammad Algahtani, Ahmad A Alenezi, Ali Alhoshani, Mohammed Alqinyah, Abdullah S. Alhamed, Khaled Alhosaini
Publikováno v:
Saudi Pharmaceutical Journal, Vol 31, Iss 10, Pp 101756- (2023)
Non-small cell lung carcinoma is a challenging disease worldwide. This study aims to determine whether combining erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, with cabozantinib, a mesenchymal-epithelial transition factor (c-Met) in
Externí odkaz:
https://doaj.org/article/783dc35bd01445c093370055e31360d3
Autor:
Ahmed Z. Alanazi, Salim S. Al-Rejaie, Mohammed M. Ahmed, Khalid Alhazzani, Khaled Alhosaini, Homood M. As Sobeai, Sary Alsanea, Perwez Alam, Omer M. Almarfadi, Ali S. Alqahtani, Abdullah S. Alhamed, Mohammed Alqinyah, Hussain N. Alhamami, Mohammed F. Almutery, Mohamed Mohany
Publikováno v:
Saudi Pharmaceutical Journal, Vol 31, Iss 8, Pp 101669- (2023)
Previous investigations have shown that D. viscosa herbal extract is often used to treat a variety of diseases. Therefore, the purpose of this study was to investigate any additional potential impacts on rat liver and kidney damage induced by diabete
Externí odkaz:
https://doaj.org/article/602507ebe5c640fbb50a64087a4c681e
Autor:
Khalid Alhazzani, Abdullah Almangour, Abdulaziz Alsalem, Mohammed Alqinyah, Abdullah S. Alhamed, Hussain N. Alhamami, Ahmed Z. Alanazi
Publikováno v:
Diseases, Vol 11, Iss 4, p 147 (2023)
Background: Dasatinib, nilotinib, and sorafenib are clinically proven tyrosine kinase inhibitors (TKIs) used for the treatment of leukemia and hepatocellular carcinoma. However, there is a growing concern regarding cardiotoxicity associated with thei
Externí odkaz:
https://doaj.org/article/d71b5d579a6f42498ea9287f14db0cd9
Autor:
Ahmed Z. Alanazi, Khalid Alhazzani, Salah Q. Alrewily, Khaldoon Aljerian, Mohammad M. Algahtani, Qamraa H. Alqahtani, Dhanush Haspula, Abdullah S. Alhamed, Mohammed Alqinyah, Mohammad Raish
Publikováno v:
Pharmaceuticals, Vol 16, Iss 7, p 921 (2023)
Dasatinib (DASA) is a novel tyrosine kinase inhibitor, approved for leukemia treatment. However, the long-term use of DASA induces several complications, especially liver damage. On the other hand, Naringenin (NGN) is a potent antioxidant and anti-in
Externí odkaz:
https://doaj.org/article/671e7d1387084c2bbfeb0d8b8993df42
Autor:
Mohammed Alqinyah, Abdullah S. Alhamed, Hajar O. Alnefaie, Mohammad M. Algahtani, Amira M. Badr, Abdullah M. Albogami, Mohamed Mohany, Yasseen A. Alassmrry, Adel F. Alghaith, Hussain N. Alhamami, Khalid Alhazzani, Ahmed Z. Alanazi, Omar Awad Alsaidan
Publikováno v:
Biomedicines, Vol 11, Iss 6, p 1637 (2023)
Persistent challenges complicating the treatment of breast cancer remain, despite some recent undeniable successes. Sufficient evidence currently exists demonstrating the crucial role of inflammation, characterized by the enhanced activation of Toll-
Externí odkaz:
https://doaj.org/article/ce990228432e42f3abd632c9d4c59f32
Autor:
Omar Awad Alsaidan, Ameeduzzafar Zafar, Mohd Yasir, Sami I. Alzarea, Mohammed Alqinyah, Mohammad Khalid
Publikováno v:
Gels, Vol 8, Iss 11, p 687 (2022)
Conventional eye drops are most commonly employed topically in the eye for the management of bacterial conjunctivitis. Eye drops have a low corneal residence time and 90–95% of the administered dose is eliminated from the eye by blinking and the na
Externí odkaz:
https://doaj.org/article/c9615c6b5ae64a958a2ab0c42c44d5b7
Autor:
Adel F. Alghaith, Gamal M. Mahrous, Gamal A. Shazly, Diaa Eldin Z. Zidan, Abdullah S. Alhamed, Mohammed Alqinyah, Mohammed M. Almutairi, Saeed A. Syed
Publikováno v:
Polymers, Vol 14, Iss 20, p 4298 (2022)
Flibanserin (FLB) is a drug used for female hypotensive sexual desire disorder approved by the FDA in August 2015. FLB exhibits extensive hepatic first-pass metabolism and low aqueous solubility, hence poor oral bioavailability. In this study, beta h
Externí odkaz:
https://doaj.org/article/5ecb174e43a645d58e588052982c9c22
Autor:
Mushtaq A. Ansari, Ahmed Nadeem, Saleh A. Bakheet, Sabry M. Attia, Mudassar Shahid, Faris S. Alyousef, Mohammed A. Alswailem, Mohammed Alqinyah, Sheikh F. Ahmad
Publikováno v:
Molecules, Vol 26, Iss 7, p 1839 (2021)
Rheumatoid arthritis (RA) is a chronic inflammatory disease mainly affecting the synovial joints. A highly potent antagonist of C-C chemokine receptor 5 (CCR5), maraviroc (MVC), plays an essential role in treating several infectious diseases but has
Externí odkaz:
https://doaj.org/article/a5563e46444e4e6892d0b3634f58b330